- R&D project leader for NASH siRNA program

- International Project Leader TA Cardiometabolism for two programs leading them to achieve Start of Development

Research Project Leader in research collaboration with Gubra on Novel PolyAgonists for Obesity

Research project leader in a research collaboration with Gubra to develop next generation obesity treatments (Link) delivering a clinical candidate

- Research project lead for an early incretin portfolio project - Applying molecular pharmacology investigating GPCR signaling bias and receptor kinetics- Support hypothesis generating activities for differentiation of marketed and clinically investigated incretin therapies by pre-clinical mode of action studies- Driving the concept of biomarker strategies for target engagement and physiological response markers to support PK/PD understanding to facilitate decision making in projects - Heading an in vitro pharmacology laboratory supervising technical staff and a Master student

- Responsibility for biomarker strategies as integral part of early clinical development plans within the therapeutic area of cardiometabolic diseases (indications type 2 diabetes, obesity, and NASH/NAFLD)- Translational Medicine and Biomarker Expert for the VAP-1 inhibitor program in NASH/NAFLD (Pharmaxis VAP-1 inhibitor BI 1467335/PXS-4728A http://www.pharmaxis.com.au/product-pipeline/amine-oxidase-platform/ssao-inhibitor-pxs4728a/)- Translational Medicine and Biomarker Expert for the GLP-1R/GCGR agonist program - Responsible for leading translational research activities including external collaborations (e.g. Mainz Gutenberg Heart study; IMI 2-NASH call)- Biomarker representative acting at the interface between research and development to facilitate transition of projects towards early clinical development including co-ordination of fit-for purpose biomarker assay development and pharmacogenomics strategies

- Project leader in projects from early discovery up to start of pre-clinical development- Project leader in research collaboration Zealand Pharma on GLP-1R/GCGR agonist, delivery of pre-clinical development candidate (https://www.zealandpharma.com/glp1glucagon-dualacting-agonist/)- Lead the process for selecting a 2nd target for continued collaboration with Zealand Pharma leading to long-acting amyling program now in Ph1(https://www.zealandpharma.com/longacting-amylin-analog/) - Leading projects in indications of type 2 diabetes, obesity, and atherosclerosis (dyslipidemia) comprising modalities of small molecules, peptides, and antibodies- Reviewing in-licensing opportunities- Support clinical programs by advancing scientific knowledge and expertise by pre-clinical studies - Established in vitro pancreatic islet lab to support projects in phases of target discovery (e.g. GPR142) , lead-optimization, and clinical compounds - Leading target identification, validation, and biomarker discovery activities- Head of an in vitro pharmacology laboratory supervising technicians and a postdoctoral fellow

- From 06/2006 Junior Research Group LeaderIndependent project researcher with supervising responsibilities for technical staff and students- Until 06/2006 Postdoctoral-Fellow⋅Generation & phenotypic characterization of knockout mice with focus on metabolic phenotypes ⋅Leading a target discovery and validation project in an academia-industry (Develogen)collaboration (Federal Ministry of Education and Research grant) in the area of type 2 diabetes/obesity⋅Supervising PhD students

- Functional characterization, cell biology, and biochemistry of glucose transporters 8 and 9 - Supervising Master students